Rufinamide is an
anticonvulsant medication. It is acclimated in aggregate with added medication
and analysis to amusement Lennox–Gastaut affection and assorted added access
disorders. Rufinamide, a triazole derivative, was developed in 2004 by Novartis
Pharma, AG, and is bogus by Eisai.
Rufinamide was accustomed by
the US Food and Biologic Administration on November 14, 2008 as accessory
analysis of seizures associated with Lennox-Gastaut affection in accouchement 4
years and earlier and adults. Its official FDA-approved labeling does not
acknowledgment use in the analysis of fractional seizures inasmuch as analytic
trials submitted to the FDA were marginal. However, several contempo analytic
trials advance that the biologic has ability for fractional seizures It is
marketed beneath the cast name Banzel. It is aswell marketed in the European
Union beneath the cast name Inovelon.
The apparatus of action of
rufinamide is unknown. There is some affirmation that rufinamide can attune the
gating of voltage-gated sodium channels, a accepted ambition for antiepileptic
drugs. A contempo abstraction indicates attenuate furnishings on the voltage-dependence
of gating and the time advance of inactivation in some sodium approach isoforms
that could abate neuronal excitability. However, this action cannot explain the
different spectrum of action of rufinamide.
No comments:
Post a Comment